Company Overview and News

 
Actinogen Medical attracts $15 million to progress Alzheimer’s disease therapy

2018-05-23 proactiveinvestors.com.au
Actinogen Medical Ltd (ASX:ACW) has successfully raised $15 million through an institutional placement at a price of 5 cents per share.

 
Actinogen Medical enrols first UK patient in Alzheimer’s therapy trial

2017-08-16 proactiveinvestors.com.au
Actinogen Medical (ASX:ACW) has enrolled its first UK patient into XanADu, its international Phase II efficacy and safety trial of Xanamem therapy in patients with mild Alzheimer’s disease.

 
Actinogen Medical begins landmark Alzheimer’s disease clinical trial

2017-05-16 proactiveinvestors.com.au
Actinogen Medical (ASX:ACW) has reached a major milestone with the first patient treated in XanADu, its Phase II clinical trial of Xanamem in Alzheimer’s disease.

 
Actinogen Medical on track to begin Alzheimer’s disease trial

2017-02-10 proactiveinvestors.com.au
Actinogen Medical (ASX:ACW) has received the approval in the UK to conduct its Phase II clinical trial of Xanamem™ for mild Alzheimer’s disease.

 
Actinogen Medical in an ASX trading halt

2016-12-29 proactiveinvestors.com.au
Actinogen requested the halt pending details regarding Actinogen Medical’s application to the FDA to initiate its XanADu Phase II clinical trial in the US of Xanamem in the treatment of Alzheimer’s disease.

 
Actinogen Medical Ltd to enhance safety profile of Alzheimer’s drug study

2016-06-08 proactiveinvestors.com.au
Actinogen Medical Ltd (ASX:ACW) is making progress in its Phase II clinical trial of its promising new Alzheimer’s drug Xanamem after discussions with the U.S. FDA. The company is seeking FDA approval under an Investigational New Drug (IND) for the Phase II study of the drug. The company is interacting with the U.S. FDA to enhance the safety profile of XanADu, their pivotal global Phase II clinical trial investigating Xanamem.

 
Appendix 3B

2016-05-06 asx.com.au

 
Section 708A Notice

2016-05-06 asx.com.au

 
Appendix 4C - quarterly

2016-04-15 asx.com.au

 
Appendix 4D & Half Year Report

2016-02-19 asx.com.au

 
R&D Rebate

2016-02-09 asx.com.au

 
Appendix 4C - quarterly

2016-01-27 asx.com.au

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

16h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...